Medivation Bonds, 2.625% 1apr2017, USD (Conv.) (FIGI BBG002QP4HH1)
Domestic bonds, Convertible
Domestic bonds, Convertible
Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market
Get accessBond parameters,
prospectuses
Analyze the data in the most efficient way
Current & historical quotes from 400+ stock exchanges & OTC market
Credit ratings, financial reports
Explore the most comprehensive database
1 000 000
bonds
80 234
stocks
167 970
ETF & Funds
70 000
indices
Track your portfolio in the most efficient way
full data on over 900 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.
Register|
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of small molecule drugs to treat serious diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc. (Astellas), the ...
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of small molecule drugs to treat serious diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc. (Astellas), the Company is developing MDV3100 for multiple stages of advanced prostate cancer. As of December 31, 2011, it completed a Phase III trial in the latest stage. The Company's three subsidiaries include Medivation Prostate Therapeutics, Inc. (MPT), Medivation Neurology, Inc. (MNI) and Medivation Technologies, Inc. (MTI). MPT holds the Company’s MDV300 series technology, which is in development for the treatment of advanced prostate cancer, and MTI holds its earlier stage technologies. MNI holds its dimebon technology, which was in development for the treatment of Alzheimer’s disease and Huntington disease.
|
|
|
|
|
|
|
|
|
Explore the most comprehensive database
1 000 000
bonds
80 234
stocks
167 970
ETF & Funds
70 000
indices
Track your portfolio in the most efficient way
full data on over 900 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.
Register